Stereotactic Body Radiotherapy as treatment for low and intermediate risk prostate cancer

The results of this eight-year study conclude that CyberKnife SBRT produces excellent biochemical control rates. Median PSA levels compare favorably with other radiation modalities and strongly suggests durability of response. These results also strongly suggest that 35 Gy is as effective as 36.25 Gy for low and low-intermediate risk patients.

Frontiers in Oncology